Nissay Asset Management Corp Japan ADV Purchases 1,523 Shares of Hologic, Inc. (NASDAQ:HOLX)

Nissay Asset Management Corp Japan ADV lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 6.4% during the 2nd quarter, Holdings Channel reports. The firm owned 25,236 shares of the medical equipment provider’s stock after acquiring an additional 1,523 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in Hologic were worth $1,438,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in shares of Hologic by 141.4% in the second quarter. SG Americas Securities LLC now owns 78,026 shares of the medical equipment provider’s stock worth $4,447,000 after purchasing an additional 45,699 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Hologic by 102.9% in the second quarter. Exchange Traded Concepts LLC now owns 5,508 shares of the medical equipment provider’s stock worth $314,000 after purchasing an additional 2,794 shares during the last quarter. State Street Corp grew its holdings in shares of Hologic by 1.2% in the first quarter. State Street Corp now owns 11,584,851 shares of the medical equipment provider’s stock worth $406,628,000 after purchasing an additional 137,837 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Hologic by 1.7% in the first quarter. Alliancebernstein L.P. now owns 418,358 shares of the medical equipment provider’s stock worth $14,684,000 after purchasing an additional 7,087 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 1.7% in the first quarter. The Manufacturers Life Insurance Company now owns 1,401,237 shares of the medical equipment provider’s stock worth $49,183,000 after purchasing an additional 22,798 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Shares of Hologic stock opened at $69.78 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.04 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $18.05 billion, a P/E ratio of 27.02, a P/E/G ratio of 3.69 and a beta of 1.47. The business has a fifty day simple moving average of $57.42 and a two-hundred day simple moving average of $50.06. Hologic, Inc. has a 12 month low of $26.49 and a 12 month high of $70.35.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.38 by $0.37. The business had revenue of $822.90 million during the quarter, compared to analyst estimates of $622.96 million. Hologic had a return on equity of 31.40% and a net margin of 20.03%. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 earnings per share. Analysts predict that Hologic, Inc. will post 2.3 earnings per share for the current year.

Several research analysts have recently issued reports on the stock. Wells Fargo & Co raised their target price on shares of Hologic from $63.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday. Morgan Stanley lifted their price target on shares of Hologic from $55.00 to $68.00 and gave the company an “equal weight” rating in a report on Friday. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $45.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Needham & Company LLC lifted their price target on shares of Hologic from $64.00 to $78.00 and gave the company a “buy” rating in a report on Thursday. Finally, Stifel Nicolaus cut their price target on shares of Hologic from $52.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday, April 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. Hologic presently has a consensus rating of “Buy” and a consensus price target of $64.28.

In other news, Director Sally Crawford sold 31,950 shares of Hologic stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $51.99, for a total value of $1,661,080.50. Following the completion of the transaction, the director now owns 126,847 shares of the company’s stock, valued at approximately $6,594,775.53. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Peter J. Valenti III sold 10,493 shares of Hologic stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $54.07, for a total value of $567,356.51. The disclosure for this sale can be found here. In the last ninety days, insiders sold 243,932 shares of company stock valued at $12,507,250. 1.00% of the stock is owned by insiders.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: Cash Asset Ratio

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.